A new treatment for ischemic stroke

Read More

Our Goal

Ischemic stroke is the second leading cause of death and a major cause of disability. Avilex Pharma investigates a novel principle in treatment to meet this major medical need.
Avilex_Banner_2

Science

Avilex Pharma develops novel inhibitors of PDZ domain proteins to target a range of unmet medical needs. Our lead candidate AVLX-144 is a drug candidate for the treatment of ischemic stroke.

Read More
Avilex_Company_Home250x160

The Company

Avilex Pharma is a spin out from the University of Copenhagen, founded by Professor Kristian Strømgaard and Ass. Prof. Anders Bach of the Department of Drug Design and Pharmacology.

Read More
MarkTreherne-250x160

Latest News

Avilex Pharma appoints Mark Treherne as its new CEO. Dr. Teherne has more than 25 years’ industrial R&D experience including leading neurodegeneration at Pfizer UK.

Read More
© Copyright 2019 Avilex Pharma. All rights reserved.
Avilex Pharma, Ole Maaløes Vej 3, 2200 Copenhagen, DK